Evaluating Glutamatergic Transmission in Schizophrenia

Carol A. Tamminga, Adrienne C. Lahti, Deborah R. Medoff, Xue Min Gao, Henry H. Holcomb

Research output: Contribution to journalArticlepeer-review

47 Scopus citations


Our findings with schizophrenia and the glutamate system have relied on the characterization of the clinical response of patients to ketamine and their functional brain imaging response (rCBF) to the drug. Prior to the human studies reported here, we had evaluated the region activation characteristics and pharmacology of PCP and its congener MK 801 in animals. What I will report in this paper has been individually reported elsewhere but brought together here in a new synthesis.

Original languageEnglish (US)
Pages (from-to)113-118
Number of pages6
JournalAnnals of the New York Academy of Sciences
StatePublished - Nov 2003


  • Glutamatergic system
  • Ketamine
  • MK-801
  • Molecular targets
  • PCP
  • Psychosis
  • Schizophrenia

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science


Dive into the research topics of 'Evaluating Glutamatergic Transmission in Schizophrenia'. Together they form a unique fingerprint.

Cite this